Vistagen Therapeutics, Inc. (VTGN)
0.3079
+0.01
(+3.32%)
USD |
NASDAQ |
Sep 30, 16:00
0.2952
-0.01
(-4.12%)
After-Hours: 20:00
Vistagen Therapeutics Net Income (Quarterly) : -13.03M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.03M |
| March 31, 2026 | -16.27M |
| December 31, 2025 | -18.90M |
| September 30, 2025 | -19.42M |
| June 30, 2025 | -15.10M |
| December 31, 2024 | -14.09M |
| September 30, 2024 | -12.96M |
| June 30, 2024 | -10.73M |
| March 31, 2024 | -9.521M |
| December 31, 2023 | -6.350M |
| September 30, 2023 | -6.588M |
| June 30, 2023 | -6.903M |
| March 31, 2023 | -12.23M |
| December 31, 2022 | -9.761M |
| September 30, 2022 | -17.48M |
| June 30, 2022 | -19.78M |
| March 31, 2022 | -16.69M |
| December 31, 2021 | -10.54M |
| September 30, 2021 | -12.79M |
| June 30, 2021 | -7.744M |
| March 31, 2021 | -6.211M |
| December 31, 2020 | -5.299M |
| September 30, 2020 | -3.298M |
| June 30, 2020 | -3.127M |
| March 31, 2020 | -3.267M |
| Date | Value |
|---|---|
| December 31, 2019 | -5.962M |
| September 30, 2019 | -5.336M |
| June 30, 2019 | -6.210M |
| March 31, 2019 | -5.723M |
| December 31, 2018 | -7.217M |
| September 30, 2018 | -7.435M |
| June 30, 2018 | -4.214M |
| March 31, 2018 | -4.079M |
| December 31, 2017 | -3.005M |
| September 30, 2017 | -4.997M |
| June 30, 2017 | -2.265M |
| March 31, 2017 | -2.549M |
| December 31, 2016 | -2.638M |
| September 30, 2016 | -3.101M |
| June 30, 2016 | -1.967M |
| March 31, 2016 | -8.502M |
| December 31, 2015 | -2.147M |
| September 30, 2015 | -7.048M |
| June 30, 2015 | -29.52M |
| March 31, 2015 | -6.222M |
| December 31, 2014 | -1.090M |
| September 30, 2014 | -2.021M |
| June 30, 2014 | -4.553M |
| March 31, 2014 | -1.826M |
| December 31, 2013 | 0.131M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Onconetix, Inc. | -2.867M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.476M |
| Total Expenses (Quarterly) | 14.51M |
| EPS Diluted (Quarterly) | -0.3032 |
| Enterprise Value | -17.72M |
| Gross Profit Margin (Quarterly) | 86.65% |
| Profit Margin (Quarterly) | -882.8% |
| Earnings Yield | -553.7% |
| Normalized Earnings Yield | -553.59 |